MX2013010898A - Novedoso derivados de la pirimidina. - Google Patents

Novedoso derivados de la pirimidina.

Info

Publication number
MX2013010898A
MX2013010898A MX2013010898A MX2013010898A MX2013010898A MX 2013010898 A MX2013010898 A MX 2013010898A MX 2013010898 A MX2013010898 A MX 2013010898A MX 2013010898 A MX2013010898 A MX 2013010898A MX 2013010898 A MX2013010898 A MX 2013010898A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
novel pyrimidine
compounds
methods
novel
Prior art date
Application number
MX2013010898A
Other languages
English (en)
Inventor
Tommy Johansson
Emma Dahlstedt
Olof Smitt
Marita Hoegberg
Original Assignee
Chemilia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11159589A external-priority patent/EP2502924A1/en
Application filed by Chemilia Ab filed Critical Chemilia Ab
Publication of MX2013010898A publication Critical patent/MX2013010898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona novedosos derivados de la pirimidina de fórmula 1, métodos de preparación de estos compuestos, composiciones farmacéuticas que contienen dichos compuestos y métodos para el uso de dichos compuestos en el tratamiento de enfermedades, incluyendo el cáncer (Ver Formula) en la cual R1-R11, Z, y Y son como defindos en la especificación.
MX2013010898A 2011-03-24 2012-03-23 Novedoso derivados de la pirimidina. MX2013010898A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11159589A EP2502924A1 (en) 2011-03-24 2011-03-24 Novel pyrimidine derivatives
EP11189572 2011-11-17
PCT/EP2012/055216 WO2012127032A1 (en) 2011-03-24 2012-03-23 Novel pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2013010898A true MX2013010898A (es) 2013-12-06

Family

ID=45876788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010898A MX2013010898A (es) 2011-03-24 2012-03-23 Novedoso derivados de la pirimidina.

Country Status (12)

Country Link
US (1) US9006241B2 (es)
EP (1) EP2688883B1 (es)
JP (1) JP5886411B2 (es)
KR (1) KR20140006048A (es)
AU (1) AU2012230229A1 (es)
BR (1) BR112013024378A2 (es)
CA (1) CA2830129C (es)
DK (1) DK2688883T3 (es)
ES (1) ES2587864T3 (es)
MX (1) MX2013010898A (es)
RU (1) RU2013147417A (es)
WO (1) WO2012127032A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
EP2711364A1 (en) * 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) * 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
WO2014089450A1 (en) * 2012-12-06 2014-06-12 Senex Biotechnology, Inc. Specific inhibitors of cdk3
GB201309180D0 (en) * 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
EP3237413A4 (en) 2014-12-23 2018-09-12 FGH Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA3022395A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CN110072861B (zh) 2016-09-07 2022-11-11 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
EP3625227B1 (en) 2017-05-18 2022-09-14 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
UA124748C2 (uk) * 2017-05-18 2021-11-10 Ідорсія Фармасьютікалз Лтд N-заміщені індольні похідні
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CR20190559A (es) 2017-05-18 2020-02-10 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores del receptor de pge2
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CA3095709A1 (en) * 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
KR20230037853A (ko) 2021-09-10 2023-03-17 인하대학교 산학협력단 췌장암의 예방 또는 치료용 조성물

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226413B1 (en) 1991-06-25 2008-11-28 Aventis Pharma Sa Novel 16-(nitro-substituted methyl)pregna-1,4-dien-3,20-dion derivatives and process for producing them
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5491234A (en) 1992-03-30 1996-02-13 Pfizer Inc. Pyrimidine derivatives for enhancing antitumor activity
EP1107957B1 (en) 1998-08-29 2006-10-18 AstraZeneca AB Pyrimidine compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN101481359A (zh) 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
DE10007411A1 (de) 2000-02-18 2001-08-23 Bayer Ag Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2006201264A1 (en) 2000-09-15 2006-04-27 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
CA2422380C (en) 2000-09-15 2009-03-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2006201263B2 (en) 2000-09-15 2008-10-30 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
AU2006201265B2 (en) 2000-09-15 2008-09-04 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2006201230B8 (en) 2000-09-15 2008-09-25 Vertex Pharmaceuticals Incorporated Triazole Compounds Useful As Protein Kinase Inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2006201262B2 (en) 2000-09-15 2008-09-04 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
AU2006201229B2 (en) 2000-12-21 2008-11-20 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful as Protein Kinase Inhibitors
CN100340555C (zh) 2000-12-21 2007-10-03 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
AU2006252047B2 (en) 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
BR0212510A (pt) 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
ES2314106T3 (es) 2001-10-17 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion.
EP1448556A1 (en) 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
MXPA04004176A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa.
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
ES2298497T3 (es) 2002-01-23 2008-05-16 Bayer Pharmaceuticals Corporation Inhibidores de quinasa rho.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
ATE365733T1 (de) 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
AU2003261807B9 (en) 2002-08-30 2007-02-15 Eisai R & D Management Co., Ltd. Azaarene derivatives
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003285614B2 (en) 2002-12-20 2009-05-14 Pfizer Products, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004074244A2 (en) 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007526894A (ja) 2003-07-16 2007-09-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
BRPI0412596A (pt) 2003-07-16 2006-09-19 Janssen Pharmaceutica Nv derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
ATE504568T1 (de) 2003-08-07 2011-04-15 Nat Health Research Institutes Indol-verbindungen als inhibitoren der tubulin- polymerisation zur behandlung von angiogenesisbezogenen erkrankungen
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
SG145749A1 (en) 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1666518B1 (en) 2003-09-08 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid modification products and drug carriers using them
JP4205543B2 (ja) 2003-09-09 2009-01-07 本田技研工業株式会社 小型船
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
US20070105839A1 (en) 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
JP4745826B2 (ja) 2003-11-14 2011-08-10 中外製薬株式会社 架橋多糖微粒子およびその製造方法
PT1687297E (pt) 2003-11-24 2014-09-18 Prometic Biosciences Inc Dímeros da triazina para o tratamento de doenças autoimunes
JP2007514775A (ja) 2003-12-19 2007-06-07 ライジェル ファーマシューティカルズ， インコーポレイテッド １−（２，４−ピリミジンジアミノ）−２−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1742634B1 (en) 2004-04-13 2010-10-27 ICAgen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US20050234583A1 (en) 2004-04-20 2005-10-20 Alexander Kantarovich Methods and systems for online embridery data processing
US20060205945A1 (en) 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013165A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20060051406A1 (en) 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1786783A1 (en) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
EP1790665B1 (en) 2004-09-07 2014-11-05 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble modified hyaluronic acid
EP1806553A4 (en) 2004-10-28 2015-03-04 Sharp Kk COOLER
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
CA2604161A1 (en) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
WO2007006926A2 (fr) 2005-07-11 2007-01-18 Sanofi-Aventis Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2007014198A1 (en) 2005-07-25 2007-02-01 Synta Pharmaceuticals Corp. 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders
US7486280B2 (en) 2005-08-04 2009-02-03 Uniplas Enterprises Pte, Ltd. Contoured capacitive touch control panel
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
US20090118310A1 (en) 2005-08-09 2009-05-07 University Of Medicine And Dentistry Of New Jersey Activated Cdc42-associated kinase (ACK) as a therapeutic target for Ras-induced cancer
EP1940804A2 (en) 2005-10-14 2008-07-09 NeuroSearch A/S Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP2009518443A (ja) 2005-12-06 2009-05-07 リゲル ファーマシューティカルズ インコーポレーティッド 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US7962290B1 (en) 2006-01-09 2011-06-14 Rigel Pharmaceuticals, Inc. Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CA2640398A1 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007115999A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN101058561B (zh) 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
CA2650403A1 (en) 2006-04-26 2007-11-08 Ito En, Ltd. Compositions comprising theaflavins and gallates thereof useful as fat absorption inhibitors
US20080082567A1 (en) 2006-05-01 2008-04-03 Bezanson Jeffrey W Apparatuses, Methods And Systems For Vector Operations And Storage In Matrix Models
MX2008015004A (es) 2006-05-26 2008-12-05 Abbott Lab Inhibidores de cinasas de tipo polo.
US7460807B2 (en) 2006-05-31 2008-12-02 Kabushiki Kaisha Toshiba Image forming apparatus and method of controlling the apparatus
CN101506175A (zh) 2006-06-15 2009-08-12 贝林格尔·英格海姆国际有限公司 作为蛋白激酶C-α抑制剂的2-苯氨基-4-（杂环基）氨基-嘧啶
AU2007263655A1 (en) 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
ATE549336T1 (de) 2006-10-19 2012-03-15 Signal Pharm Llc Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007333925B2 (en) 2006-12-15 2013-10-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
CN101563327A (zh) 2006-12-19 2009-10-21 健泰科生物技术公司 嘧啶类激酶抑制剂
JP2010513495A (ja) 2006-12-20 2010-04-30 シェーリング コーポレイション 新規なｊｎｋ阻害剤
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
JP2010520222A (ja) 2007-03-01 2010-06-10 スーパージェン， インコーポレイテッド ピリミジン−２，４−ジアミン誘導体およびｊａｋ２キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体の使用
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
CN101289444B (zh) 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
RU2455994C2 (ru) 2007-04-16 2012-07-20 Хатчисон Медифарма Энтерпрайзис Лимитед Пиримидиновые производные
WO2008129380A1 (en) 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
BRPI0814821A2 (pt) 2007-07-16 2015-02-03 Astrazeneca Ab Composto, composição farmacêutica, e, processo para preparar um composto
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2008296545B2 (en) 2007-08-28 2011-09-29 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
CA2707046A1 (en) 2007-11-28 2009-06-11 Nathanael S. Gray Small molecule myristate inhibitors of bcr-abl and methods of use
US20090142832A1 (en) 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
CA2707653A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP5586482B2 (ja) 2008-02-22 2014-09-10 ライジェル ファーマシューティカルズ， インコーポレイテッド アテローム性動脈硬化症の治療のための２，４−ピリミジンジアミンの使用
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
EP2303861B1 (en) 2008-06-17 2014-04-23 AstraZeneca AB Pyridine compounds
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
DE102008058501B4 (de) * 2008-11-21 2011-11-10 Eisenmann Ag Verfahren zum Betreiben einer Anlage zur Herstellung von Bioethanol
EP2241555A1 (en) * 2009-04-14 2010-10-20 Universita' Degli Studi Di Milano New RAC1 inhibitors as potential pharmacological agents for heart failure treatment
US20130023534A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Pyrazolyl-pyrimidines as kinase inhibitors
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5607241B2 (ja) * 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
JP2012209902A (ja) 2011-03-30 2012-10-25 Semiconductor Components Industries Llc 入出力回路
JP6212827B2 (ja) * 2012-07-24 2017-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド誘導体、およびｇｐｒ１１９モジュレーターとしてのそれらの使用

Also Published As

Publication number Publication date
AU2012230229A1 (en) 2013-10-10
EP2688883A1 (en) 2014-01-29
CA2830129A1 (en) 2012-09-27
BR112013024378A2 (pt) 2016-12-13
WO2012127032A1 (en) 2012-09-27
US20140045845A1 (en) 2014-02-13
JP5886411B2 (ja) 2016-03-16
CN103619835A (zh) 2014-03-05
KR20140006048A (ko) 2014-01-15
EP2688883B1 (en) 2016-05-18
CA2830129C (en) 2016-07-19
JP2014508795A (ja) 2014-04-10
US9006241B2 (en) 2015-04-14
DK2688883T3 (en) 2016-09-05
RU2013147417A (ru) 2015-04-27
ES2587864T3 (es) 2016-10-27

Similar Documents

Publication Publication Date Title
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2012013274A (es) Novedosos derivados de la pirimidina.
TN2015000281A1 (fr) Lactames condenses aryliques et heteroaryliques
MX343706B (es) Derivados heterocíclicos novedosos.
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
PH12015501385A1 (en) Autotaxin inhibitors
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MY177344A (en) Compounds and their methods of use
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2014012695A (es) Derivados de isoindolona.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MY191358A (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
MX349004B (es) Nuevos compuestos.
PH12015500376B1 (en) Novel bicyclic pyridinones
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TW201613864A (en) Novel compounds
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MY152018A (en) Indole derivatives as anticancer agents
TN2013000327A1 (en) Novel heterocyclic derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal